Table 1.

Clinical characteristic of COVID-19 patients across the globe

Geographical area	America	Asia	Europe	America vs. Asia [% Difference, (95% CI), p value]	America vs. Europe [% Difference, (95% CI), p value]	Asia vs. Europe [% Difference, (95% CI), p value]
Total number	7287	6776	2624
Average age (years)	61.73	51.12	62.37	NA	NA	NA
Male (%)	58.21	54.51	69.58	3.7 (2.05–5.34), p < 0.0001	11.37 (9.24–13.46), p < 0.0001	15.07 (12.91–17.19), p < 0.0001
Obesity (%)	37.65	17.9	29.63	19.75 (18.29–21.19), p < 0.0001	8.02 (5.91–10.09), p < 0.0001	11.73 (9.75–13.73), p < 0.0001
DM (%)	30.97	12.39	16.08	18.58, (17.24–19.9), p < 0.0001	14.89 (13.08–16.64), p < 0.0001	3.69 (2.08–5.34), p < 0.0001
HTN (%)	47.57	20.8	44.5	26.77 (25.25–28.27), p < 0.0001	3.07 (0.82–5.30), p < 0.0074	23.7 (21.55–25.58), p < 0.0001
Smokers current or past (%)	15.08	17.46	21.32	2.38 (1.14–3.61), p = 0.0001	6.24 (4.47–8.05), p < 0.0001	3.86 (2.05–5.71), p < 0.0001
CAD/CVD (%)	17	10.91	14.65	6.09 (4.94–7.23), p < 0.0001	2.35 (0.69–3.94), p = 0.0058	3.74 (2.2–5.33), p < 0.0001
Asthma (%)	10.15	2.25	4.5	7.9 (7.11–8.69), p < 0.0001	5.65 (4.54–6.69), p < 0.0001	2.25 (1.39–3.17), p < 0.0001
COPD (%)	10.25	2.13	13.1	8.12 (7.33–8.91), p < 0.0001	2.85 (1.39–4.36), p = 0.0001	10.97 (9.64–12.36), p < 0.0001
Lung disease (%)	15.48	3.56	19	11.92 (10.97–12.87), p < 0.0001	3.52 (1.8–5.27), p < 0.0001	15.44 (13.83–17.05) p < 0.0001
CKD (%)	19.15	2.04	5.35	17.11 (16.14–18.08), p < 0.0001	13.8 (12.5–15.04), p < 0.0001	3.31 (2.04–4.29), p < 0.0001
Liver problems (%)	3.65	2.16	3	1.49 (0.92–2.05), p < 0.0001	0.65 (– 0.18 to 1.41), p = 0.13	0.84 (0.11–1.63), p < 0.02
Immunosuppression/HIV (%)	7.52	0.84	5.1	6.68 (6.03–7.34), p < 0.0001	2.42 (1.33–3.44), p < 0.0001	4.26 (3.41–5.19), p < 0.0001
Malignancy active or past (%)	6.64	2.3	9.12	4.34 (3.65–5.02), p < 0.0001	2.48 (1.25–3.77), p < 0.0001	6.82 (5.67–8.03), p < 0.0001
In-hospital mortality (%)	22.23	13.15	22.9	9.08 (7.82–10.33), p < 0.0001	0.67 (– 1.19 to 2.58), p = 0.49	9.75 (7.95–11.58), p < 0.0001